The accelerated approval is supported by results from part 1 of the ESSENCE trial
Inclacumab was generally well tolerated in THRIVE-131
Fourteenth breakthrough therapy designation granted by FDA across the oncology portfolio of Daiichi Sankyo
OGSIVEO is the first and only therapy to receive marketing authorization in the EU for the treatment of desmoid tumors
The CRDMO segment contributed Rs. 452.7 crore, recording a robust 70.5 per cent YoY increase
The new facility will enhance AbbVie’s chemical synthesis capacity to support domestic production of current and next-generation neuroscience, immunology, and oncology medicines
EBITDA stood at Rs. 100.1 crore with a margin of 16.1 per cent
Subscribe To Our Newsletter & Stay Updated